blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2147096

EP2147096 - Modified factor VII polypeptides and uses thereof [Right-click to bookmark this link]
Former [2010/04]MODIFIED FACTOR VII POLYPETIDES AND USES THEREOF
[2013/44]
StatusNo opposition filed within time limit
Status updated on  29.01.2016
Database last updated on 10.07.2024
Most recent event   Tooltip01.09.2017Lapse of the patent in a contracting state
New state(s): CY		published on 04.10.2017  [2017/40]
Applicant(s)For all designated states
Catalyst Biosciences, Inc.
260 Littlefield Avenue
South San Francisco, CA 94080 / US
[2010/04]
Inventor(s)01 / MADISON, Edwin, L.
558 48th Avenue
San Francisco, CA 94121 / US
02 / THANOS, Christopher, D.
3579 Sacramento Street
San Francisco, CA 94118 / US
03 / RUGGLES, Sandra, Waugh
344 East Olive Avenue
Sunnyvale, CA 94086 / US
04 / COUGHLIN, Shaun
2 Turtle Rock Ct.
Tiburon, CA 94920 / US
 [2010/23]
Former [2010/16]01 / MADISON, Edwin, L.
558 48th Avenue
San Francisco, CA 94121 / US
02 / THANOS, Christopher, D.
3759 Sacramento Street
San Francisco, CA 94118 / US
03 / RUGGLES, Sandra, Waugh
344 East Olive Avenue
Sunnyvale, CA 94086 / US
04 / COUGHLIN, Shaun
2 Turtle Rock Ct.
Tiburon, CA 94920 / US
Former [2010/04]01 / MADISON, Edwin, L.
558 48th Avenue
San Francisco, CA 94121 / US
02 / THANOS, Christopher, D.
250 Pt. Lobos Avenue, Apt. 504
San Francisco, CA 94121 / US
03 / RUGGLES, Sandra, Waugh
344 East Olive Avenue
Sunnyvale, CA 94086 / US
04 / COUGHLIN, Shaun
2 Turtle Rock Ct.
Tiburon, CA 94920 / US
Representative(s)Boult Wade Tennant LLP
Salisbury Square House
8 Salisbury Square
London EC4Y 8AP / GB
[N/P]
Former [2014/02]Boult Wade Tennant
Verulam Gardens
70 Gray's Inn Road
London WC1X 8BT / GB
Former [2010/04]Baldock, Sharon Claire
Boult Wade Tennant Verulam Gardens 70 Gray's Inn Road
London WC1X 8BT / GB
Application number, filing date08742852.011.04.2008
[2010/04]
WO2008US04795
Priority number, dateUS20070923512P13.04.2007         Original published format: US 923512 P
[2010/04]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2008127702
Date:23.10.2008
Language:EN
[2008/43]
Type: A2 Application without search report 
No.:EP2147096
Date:27.01.2010
Language:EN
The application published by WIPO in one of the EPO official languages on 23.10.2008 takes the place of the publication of the European patent application.
[2010/04]
Type: B1 Patent specification 
No.:EP2147096
Date:25.03.2015
Language:EN
[2015/13]
Search report(s)International search report - published on:EP19.03.2009
ClassificationIPC:C07K14/745, A61K38/36, A61P7/04
[2013/44]
CPC:
C07K14/745 (EP,KR,US); A61K38/36 (EP,US); A61K38/37 (KR);
A61K45/06 (EP,US); A61P1/04 (EP); A61P13/10 (EP);
A61P19/02 (EP); A61P25/00 (EP); A61P43/00 (EP);
A61P7/00 (EP); A61P7/04 (EP); C12N15/11 (KR);
A61K38/00 (EP,US) (-)
C-Set:
A61K38/36, A61K2300/00 (EP,US)
Former IPC [2010/04]C12N9/64, C07K14/745
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2010/04]
Extension statesAL13.11.2009
BA13.11.2009
MK13.11.2009
RS13.11.2009
TitleGerman:Modifizierte Faktor-VII-Polypeptide und Verwendungen davon[2013/44]
English:Modified factor VII polypeptides and uses thereof[2013/44]
French:Polypeptides du facteur VII modifiés et leurs utilisations[2013/44]
Former [2010/04]MODIFIZIERTE FAKTOR-VII-POLYPEPTIDE UND VERWENDUNGEN DAVON
Former [2010/04]MODIFIED FACTOR VII POLYPETIDES AND USES THEREOF
Former [2010/04]POLYPEPTIDES DU FACTEUR VII MODIFIÉS ET LEURS UTILISATIONS
Entry into regional phase13.11.2009National basic fee paid 
13.11.2009Designation fee(s) paid 
13.11.2009Examination fee paid 
Examination procedure15.04.2009Request for preliminary examination filed
International Preliminary Examining Authority: EP
13.11.2009Amendment by applicant (claims and/or description)
13.11.2009Examination requested  [2010/04]
26.02.2010Despatch of a communication from the examining division (Time limit: M06)
08.09.2010Reply to a communication from the examining division
12.04.2011Despatch of a communication from the examining division (Time limit: M06)
24.10.2011Reply to a communication from the examining division
02.02.2012Despatch of a communication from the examining division (Time limit: M06)
13.08.2012Reply to a communication from the examining division
13.02.2013Despatch of a communication from the examining division (Time limit: M04)
19.04.2013Reply to a communication from the examining division
10.12.2013Communication of intention to grant the patent
22.04.2014Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
17.06.2014Communication of intention to grant the patent
06.10.2014Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
30.10.2014Communication of intention to grant the patent
11.02.2015Fee for grant paid
11.02.2015Fee for publishing/printing paid
11.02.2015Receipt of the translation of the claim(s)
Divisional application(s)EP12156573.3  / EP2481797
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  26.02.2010
Opposition(s)05.01.2016No opposition filed within time limit [2016/09]
Fees paidRenewal fee
23.04.2010Renewal fee patent year 03
26.04.2011Renewal fee patent year 04
23.04.2012Renewal fee patent year 05
23.04.2013Renewal fee patent year 06
23.04.2014Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY25.03.2015
EE25.03.2015
HR25.03.2015
LT25.03.2015
LV25.03.2015
MC25.03.2015
MT25.03.2015
[2017/40]
Former [2017/03]EE25.03.2015
HR25.03.2015
LT25.03.2015
LV25.03.2015
MC25.03.2015
MT25.03.2015
Former [2016/01]EE25.03.2015
HR25.03.2015
LT25.03.2015
LV25.03.2015
MC25.03.2015
Former [2015/49]EE25.03.2015
HR25.03.2015
LT25.03.2015
LV25.03.2015
Former [2015/39]HR25.03.2015
LT25.03.2015
LV25.03.2015
Former [2015/36]HR25.03.2015
LT25.03.2015
Former [2015/35]LT25.03.2015
Cited inInternational search[XY]WO2004083361  (MAXYGEN HOLDINGS LTD, et al) [X] 1-21,38-118 * page 14 - page 16 * * page 17, line 13 - page 18, line 12 * [Y] 22-29;
 [XA]WO2006114105  (MAXYGEN HOLDINGS LTD, et al) [X] 1-21,38-118 * page 34, line 18 - line 21 * * page 2, line 29 - page 3, line 14 * [A] 22-37;
 [X]WO2007031559  (NOVO NORDISK AS [DK], et al) [X] 1-21,38-118 * page 21, line 30 - line 33 * * page 31, line 22 *;
 [DY]  - GENG J P ET AL, "Properties of a recombinant chimeric protein in which the gamma-carboxyglutamic acid and helical stack domains of human anticoagulant protein C are replaced by those of human coagulation factor VII.", THROMBOSIS AND HAEMOSTASIS MAY 1997, (199705), vol. 77, no. 5, ISSN 0340-6245, pages 926 - 933, XP008098458 [DY] 22-29 * page 926, column R, paragraph 4 *
 [DY]  - SHAH A ET AL, "Manipulation of the membrane binding site of vitamin K-dependent proteins: enhanced biological function of human factor VII", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC.; US, (19980414), vol. 95, no. 8, ISSN 0027-8424, pages 4229 - 4234, XP002092845 [DY] 22-29 * Page 4231 paragraph binding left- and right-hand column *

DOI:   http://dx.doi.org/10.1073/pnas.95.8.4229
 [DA]  - HARVEY S B ET AL, "Mutagenesis of the gamma-Carboxyglutamic Acid Domain of Human Factor VII to Generate Maximum Enhancement of the Membrane Contact Site", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,; US, (20030307), vol. 278, no. 10, ISSN 0021-9258, pages 8363 - 8369, XP002306018 [DA] 22-37 * page 8366, paragraph bridging left- and right-hand columns *

DOI:   http://dx.doi.org/10.1074/jbc.M211629200
 [A]  - RUF W, "Factor VIIa residue Arg290 is required for efficient activation of the macromolecular substrate factor X.", BIOCHEMISTRY 27 SEP 1994, (19940927), vol. 33, no. 38, ISSN 0006-2960, pages 11631 - 11636, XP002493195 [A] 10-21 * the whole document *

DOI:   http://dx.doi.org/10.1021/bi00204a026
by applicantUS4892538
 US5283187
 US2002166130
 US2004133930
 US2004146938
 WO2004083661
 WO2004111242
 US2006115874
    - EISENBERG ET AL., FARADAY SYMP. CHEM. SOC., (1982), vol. 17, pages 109 - 120
    - RUAN, H. ET AL., GENE, (1997), vol. 188, pages 35 - 39
    - ZACCOLO, M. ET AL., J MOL. BIOL, (1996), vol. 255, pages 589 - 603
    - SROUR ET AL., THROMB HAEMOST., (2003), vol. 90, no. 3, pages 398 - 405
    - VAN BUUREN ET AL., DIG DIS SCI, (2002), vol. 47, pages 2134 - 2135
    - GEROTZIAFAS ET AL., AM J HERNATOL, (2002), vol. 69, pages 219 - 222
    - RIZOLI ET AL., CRIT CARE, (2006), vol. 10, page R178
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.